Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.37 |
| ▸ | PEPD | P12955 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRM8 | O00222 | 1/20 | 0.34 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7856444 | 1.00 | GABRR1 (0.43) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| SCHEMBL10578737 | 0.90 | PEPD (0.43) | PEPDLMNAGRM4 | |
| SCHEMBL336245 | 0.90 | PEPD (0.48) | PEPDACELMNA | |
| SCHEMBL4464323 | 0.90 | PEPD (0.48) | PEPDACELMNA | |
| SCHEMBL5525138 | 0.90 | PEPD (0.48) | PEPDACELMNA | |
| SCHEMBL598373 | 0.90 | PEPD (0.43) | PEPDLMNAGRM4 | |
| SCHEMBL34169 | 0.90 | PEPD (0.43) | PEPDLMNAGRM4 | |
| SCHEMBL130870 | 0.90 | PEPD (0.43) | PEPDLMNAGRM4 | |
| SCHEMBL169047 | 0.87 | GABRR1 (0.44) | GABRR1SLC1A2SLC1A1GABRR2ACE | |
| SCHEMBL10739888 | 0.87 | PEPD (0.42) | PEPDLMNAGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598281-B2 | Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20070197605-A1 | ARYLCYCLOAKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1051655-B1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1051655-A4 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20010016731-A1 | Methods and apparatus for accelerated orthokeratology | DEVORE DALE (US) | 2001-08-23 | — | — | US | disclosed |
| US-6161544-A | Methods for accelerated orthokeratology | KERATOFORM, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1051655-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | Ista Pharmaceuticals, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| US-6037476-A | Process for making cyclic imides | ALBEMARLE CORPORATION (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1999039238-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | KERATOFORM, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| US-4642315-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1987-02-10 | — | — | US | disclosed |
| EP-0013107-A1 | 16-Hydroxy-16-vinyl (or cyclopropyl)-prostan-1-ols and pharmaceutical compositions containing the same | AMERICAN CYANAMID COMPANY (US) | 1980-07-09 | — | — | EP | disclosed |
| US-4206151-A | BRONCHODILATOR, ANTISECRETORY, HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1980-06-03 | — | — | US | disclosed |
| EP-0002590-A1 | Novel prostaglandin compounds, processes for the preparation thereof and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-06-27 | — | — | EP | disclosed |
| US-4149017-A | FERTILITY CONTROL, ANTIULCER AGENTS, BRONCHODILATOR, ANTICOAGULANT | MILES LABORATORIES, INC. (US) | 1979-04-10 | — | — | US | disclosed |
| US-4139717-A | 1,3-Dicarbonyl compounds | TEIJIN LIMITED (JP) | 1979-02-13 | — | — | US | disclosed |
| US-4115453-A | SMOOTH MUSCLE ACTIVITY, ANTICOAGULANTS, ANTISECRETORY, HYPOTENSIVE | MILES LABORATORIES, INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-4115438-A | SMOOTH MUSCLE ACTIVITY, ANTICLOTTING, ANTISECRETORY, BLOOD PRESSURE | MILES LABORATORIES, INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-4108892-A | ANTICOAGULATNS, SMOOTH MUSCLE ACTIVITY MODIFIERS, ANTISECRETORY | MILES LABORATORIES, INC. (US) | 1978-08-22 | — | — | US | disclosed |
| US-4074063-A | ANTISECRETORY AGENTS, ANTICOAGULANTS, HYPOTENSIVE AGENTS | MILES LABORATORIES, INC. (US) | 1978-02-14 | — | — | US | disclosed |
| US-4009196-A | HYPOTENSIVE AGENTS, BRONCHODILATORS, PROSTAGLANDIN ANALOGS | TEIJIN LIMITED (JA) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197605-A1 | ARYLCYCLOAKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | PPARA, PPARG, GPR119 | GABRR1 954/4885SLC1A2 2678/4885SLC1A1 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.